Pancreatic Cancer Therapeutics are we doing things Right?

Abstract

Pancreatic adenocarcinoma (PDAC) is one of the most lethal cancers. Among su-pramesocolic cancers, PDAC carries the worst prognosis because early detection re-mains a difficult task. Many treatment regimens failed to show improvement in terms of OS and DFS. In this review, we try to focus on PDAC from a molecular perspective. We identified how the 10 hallmarks of cancer apply in PDAC. K-ras mutation (the setter) was the triggering factor for all of them. Moreover, G12D mutation is a crucial step for PDAC to occur. Since this gene has many downstream pathways (spikers), it’s hard to hope for an effective treatment for each downstream mutation. Therefore, further re-search is required to find therapeutic drugs to target this mutation, the K-ras G12D.